Composition for treatment of inflammatory disorders

Details Composition for treatment of inflammatory disorders Composition for treatment of inflammatory disorders

2011-06-07

2011-06-07

Azpuru, Carlos A (Department: 1617)

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Liposomes

C977S801000, C977S907000

Reexamination Certificate

active

07955618

ABSTRACT:
A pharmaceutical composition for parenteral administration, comprising liposomes composed of non-charged vesicle-forming lipids, including up to 20 mole percent of an amphipathic vesicle-forming lipid derivatized with polyethyleneglycol, and optionally including not more than 10 mole percent of negatively charged vesicle-forming lipids, the liposomes having a selected mean particle diameter in the size range between about 40-200 nm and containing a water soluble corticosteroid for the site-specific treatment of inflammatory disorders, is provided.

REFERENCES:
patent: 4370349 (1983-01-01), Evans et al.
patent: 4522803 (1985-06-01), Lenk et al.
patent: 4818537 (1989-04-01), Guo
patent: 4954345 (1990-09-01), Muller
patent: 4994443 (1991-02-01), Folkman et al.
patent: 5139803 (1992-08-01), Haynes et al.
patent: 5190936 (1993-03-01), Laugier
patent: 5192528 (1993-03-01), Radhakrishnan et al.
patent: 5316771 (1994-05-01), Barenholz et al.
patent: 5356633 (1994-10-01), Woodle et al.
patent: 5569464 (1996-10-01), Endo et al.
patent: 5762918 (1998-06-01), Thorpe
patent: 5786344 (1998-07-01), Ratain et al.
patent: 5853752 (1998-12-01), Unger et al.
patent: 6028066 (2000-02-01), Unger
patent: 6090800 (2000-07-01), Unger et al.
patent: 6120751 (2000-09-01), Unger
patent: 6126966 (2000-10-01), Abra et al.
patent: 6316260 (2001-11-01), Freisleben et al.
patent: 6403056 (2002-06-01), Unger
patent: 6423735 (2002-07-01), Camden et al.
patent: 6444660 (2002-09-01), Unger et al.
patent: 6511676 (2003-01-01), Boulikas
patent: 6562371 (2003-05-01), Kawahara et al.
patent: 2002/0058060 (2002-05-01), Kan et al.
patent: 2002/0159951 (2002-10-01), Unger et al.
patent: 2003/0050236 (2003-03-01), Dawson et al.
patent: 2003/0054027 (2003-03-01), Unger
patent: 2005/0152962 (2005-07-01), Metselaar
patent: 2009/0226509 (2009-09-01), Metselaar
patent: 0 622 072 (1994-03-01), None
patent: 0 622 072 (1994-11-01), None
patent: 1 072 617 (1999-07-01), None
patent: 1 044 679 (2000-10-01), None
patent: 1 190 706 (2002-03-01), None
patent: 1 190 706 (2002-03-01), None
patent: 62-42733 (1987-02-01), None
patent: WO94/07466 (1994-04-01), None
patent: WO 94/07466 (1994-04-01), None
patent: WO 94/07468 (1994-04-01), None
patent: WO 98 42283 (1998-10-01), None
patent: WO 98 50040 (1998-11-01), None
patent: WO 98 50041 (1998-11-01), None
patent: WO 00/25748 (2000-05-01), None
patent: WO 00/38653 (2000-07-01), None
patent: WO 02/45688 (2001-12-01), None
patent: WO 02/45688 (2002-06-01), None
patent: WO 03/105805 (2003-12-01), None
patent: WO 2004 019916 (2004-03-01), None
PCT International Search Report, PCT/EP01/14633, dated May 8, 2002, 2 pages.
PCT International Preliminary Examination Report, PCT/EP01/14633, dated Apr. 2, 2003, 2 pages.
Al-Muhammad et al., Studies on the formulation and in vitro release of ophthalmic liposomes containing dexamethasone sodium phosphate, J. Microencapsulation, 1996, pp. 123-130, vol. 13, No. 2.
Farshi et al., In-vivo studies in the treatment of oral ulcers with liposomal dexamethasone sodium phosphate, J. Microencapsulation, 1996, pp. 537-544, vol. 13. No. 5.
Vion-Dury et al., Specific in Vitro Labeling of Cells with a Fluorine-19 Probe Ensapsulated in Antibody-Targeted Liposomes: A F-19 NMR Spectroscopy Study, Magnetic Resonance in Medicine, 1993, pp. 252-255, vol. 29, No. 2.
Matselaar et al., Liposomes for Intravenous Drug Targeting: Design and Applications, Mini Reviews in Medicinal Chemistry, 2002, pp. 319-329, vol. 2.
Shibata et al., Preparation and Characterization of Liposomes Incorporating Hydrophobic Poly (Amino Acid)s with Different Secondary Structure, Chemical & Pharmaceutical Bulletin, May 1994, pp. 1151-1153, vol. 42, No. 5.
Gonzalez-Rothi et al., Pulmonary Targeting of Liposomal Triamcinolone Acetonida Phosphate, Pharmaceutical Research, 1996, pp. 1699-1703, vol. 13, No. 11.
PCT International Preliminary Examination Report, PCT/NL03/00596, dated Dec. 4, 2003.
PCT International Search Report, PCT/NL03/00596, dated Dec. 7, 2004.
PCT International Preliminary Examination Report, PCT/NL03/00419, Dated Apr. 14, 2004.
PCT International Search Report, PCT/NL03/00419, dated Sep. 8, 2003.
U.S. Appl. No. 12/387,598, filed May 5, 2009, Metselaar, Composition for Treatment of Inflammatory Disorders.
Trosko et al. in Mutation Research, 480-481, pp. 219-229, 2001.
Gonzalez-Rothi et al., Pharmaceutical Research, vol. 13. No. 11 1996, pp. 1699-1703.
Office Action for U.S. Appl. No. 10/455,257, dated Aug. 9. 2004.
Office Action for U.S. Appl. No. 10/455,257, dated Mar. 3, 2005.
Office Action for U.S. Appl. No. 10/455,257, dated Oct. 3, 2005.
Office Action for U.S. Appl. No. 10/455,257, dated May 4, 2006.
Office Action for U.S. Appl. No. 10/455,257, dated Jul. 13, 2007.
Office Action for U.S. Appl. No. 10/455,257, dated Dec. 3, 2007.
Office Action for U.S. Appl. No. 10/455,257, dated Oct. 8, 2008.
Office Action for U.S. Appl. No. 10/455,257, dated Jun. 5, 2009.
Office Action for U.S. Appl. No. 10/455,257, dated Jan. 5, 2010.
Banciu et al., Liposomal glucocorticoids as tumor-targeted anti-angiogenic nanomedicine in B16 melanoma-bearing mice. Journal of Steroid Biochemistry and Molecular Biology, 2008, pp. 101-110, vol. 111.
Herr et al., Glucocorticoid use in prostate cancer and other solid tumours: implications for effectiveness of cytotoxic treatment and metastases. Lancet Oncol., 2006, pp. 425-430, vol. 7.
Rutz et al., Effects of corticosteroid use on treatment of solid tumours, The Lancet, Dec. 14, 2002, pp. 1969-1970, vol. 360.
U.S. Appl. No. 11/065,692, filed Feb. 24, 2005, Schiffelers et al., Vesicle-Encapsulated Corticosteroids for the Treatment of Cancer.

Affiliated with

Also associated with

Rating

Composition for treatment of inflammatory disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Composition for treatment of inflammatory disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Composition for treatment of inflammatory disorders will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2708755